These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2396475)

  • 1. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine.
    Saluzzo JF; Smith JF
    Vaccine; 1990 Aug; 8(4):369-75. PubMed ID: 2396475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.
    Ikegami T; Hill TE; Smith JK; Zhang L; Juelich TL; Gong B; Slack OA; Ly HJ; Lokugamage N; Freiberg AN
    J Virol; 2015 Jul; 89(14):7262-76. PubMed ID: 25948740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.
    Nishiyama S; Lokugamage N; Ikegami T
    J Virol; 2016 Jan; 90(7):3735-44. PubMed ID: 26819307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation.
    Vialat P; Muller R; Vu TH; Prehaud C; Bouloy M
    Virus Res; 1997 Nov; 52(1):43-50. PubMed ID: 9453143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.
    Nishiyama S; Slack OA; Lokugamage N; Hill TE; Juelich TL; Zhang L; Smith JK; Perez D; Gong B; Freiberg AN; Ikegami T
    Virulence; 2016 Nov; 7(8):871-881. PubMed ID: 27248570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.
    Ly HJ; Lokugamage N; Nishiyama S; Ikegami T
    PLoS One; 2017; 12(9):e0185194. PubMed ID: 28926632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.
    Ly HJ; Nishiyama S; Lokugamage N; Smith JK; Zhang L; Perez D; Juelich TL; Freiberg AN; Ikegami T
    Vaccine; 2017 Dec; 35(48 Pt B):6634-6642. PubMed ID: 29061350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of two next-generation Rift Valley fever vaccines.
    Kortekaas J; Oreshkova N; van Keulen L; Kant J; Bosch BJ; Bouloy M; Moulin V; Goovaerts D; Moormann RJ
    Vaccine; 2014 Sep; 32(39):4901-8. PubMed ID: 25050973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging.
    Wichgers Schreur PJ; Oreshkova N; Moormann RJ; Kortekaas J
    J Virol; 2014 Sep; 88(18):10883-93. PubMed ID: 25008937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and transmission of Rift Valley fever viral reassortants by the mosquito Culex pipiens.
    Turell MJ; Saluzzo JF; Tammariello RF; Smith JF
    J Gen Virol; 1990 Oct; 71 ( Pt 10)():2307-12. PubMed ID: 2230736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs.
    Bouloy M; Janzen C; Vialat P; Khun H; Pavlovic J; Huerre M; Haller O
    J Virol; 2001 Feb; 75(3):1371-7. PubMed ID: 11152510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains.
    Lokugamage N; Freiberg AN; Morrill JC; Ikegami T
    J Virol; 2012 Dec; 86(24):13566-75. PubMed ID: 23035230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temperature-sensitive mutations for live-attenuated Rift Valley fever vaccines: implications from other RNA viruses.
    Nishiyama S; Ikegami T
    Front Microbiol; 2015; 6():787. PubMed ID: 26322023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.
    Parks CL; Latham T; Cahill A; O'neill RE; Passarotti CJ; Buonagurio DA; Bechert TM; D'Arco GA; Neumann G; Destefano J; Arendt HE; Obregon J; Shutyak L; Hamm S; Sidhu MS; Zamb TJ; Udem SA
    Virology; 2007 Oct; 367(2):275-87. PubMed ID: 17599381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus.
    Lihoradova OA; Indran SV; Kalveram B; Lokugamage N; Head JA; Gong B; Tigabu B; Juelich TL; Freiberg AN; Ikegami T
    PLoS Negl Trop Dis; 2013; 7(4):e2181. PubMed ID: 23638202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy.
    Kalveram B; Lihoradova O; Indran SV; Ikegami T
    J Vis Exp; 2011 Nov; (57):e3400. PubMed ID: 22083261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome.
    Ayers VB; Huang YS; Dunlop JI; Kohl A; Brennan B; Higgs S; Vanlandingham DL
    Viral Immunol; 2023 Jan; 36(1):33-40. PubMed ID: 36399689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development.
    Caplen H; Peters CJ; Bishop DH
    J Gen Virol; 1985 Oct; 66 ( Pt 10)():2271-7. PubMed ID: 4045430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice.
    Vialat P; Billecocq A; Kohl A; Bouloy M
    J Virol; 2000 Feb; 74(3):1538-43. PubMed ID: 10627566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mutations in the M RNA of a candidate vaccine strain of Rift Valley fever virus.
    Takehara K; Min MK; Battles JK; Sugiyama K; Emery VC; Dalrymple JM; Bishop DH
    Virology; 1989 Apr; 169(2):452-7. PubMed ID: 2705307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.